Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

What Was Tested

This randomized controlled trial looks at Amylin (Islet Amyloid Polypeptide).

The autoimmune-mediated destruction of pancreatic beta-cells in Type 1 diabetes mellitus renders patients deficient in two glucoregulatory peptide hormones, insulin and amylin.

With insulin replacement alone, most patients do not achieve glycaemic goals.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, multicenter and parallel-group.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Amylin (Islet Amyloid Polypeptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Amylin (Islet Amyloid Polypeptide) group a baseline to be compared against.

More than one site took part, so the participants came from several places.

What Was Measured

Topics PubMed links to this paper include Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemic Agents, Insulin and Islet Amyloid Polypeptide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.